Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SLNO | US
-0.39
-1.16%
Healthcare
Diagnostics & Research
30/06/2024
20/03/2026
33.22
33.48
33.75
32.63
Soleno Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia Inc. and changed its name to Soleno Therapeutics Inc. in May 2017. Soleno Therapeutics Inc. was incorporated in 1999 and is based in Redwood City California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
56.2%1 month
52.0%3 months
51.6%6 months
69.7%-
-
7.41
0.00
0.00
0.02
-
-
-66.53M
1.29B
1.29B
-
-
-
-
-44.62
10.39
20.70
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
8.95
Range1M
9.71
Range3M
18.73
Rel. volume
0.98
Price X volume
51.38M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Quidel Corporation | QDEL | Diagnostics & Research | 15.24 | 1.02B | -8.03% | n/a | 87.31% |
| NeoGenomics Inc | NEO | Diagnostics & Research | 7.96 | 1.02B | -2.69% | n/a | 66.22% |
| CareDx Inc | CDNA | Diagnostics & Research | 17.15 | 904.49M | -2.50% | n/a | 11.88% |
| CASTLE BIOSCIENCES INC | CSTL | Diagnostics & Research | 25 | 693.42M | -2.72% | n/a | 5.94% |
| Atossa Genetics Inc | ATOS | Diagnostics & Research | 5.33 | 670.28M | 3.90% | n/a | 0.00% |
| Personalis Inc | PSNL | Diagnostics & Research | 7.26 | 478.69M | 0.97% | n/a | 41.56% |
| Fulgent Genetics Inc | FLGT | Diagnostics & Research | 15.51 | 469.90M | -0.32% | n/a | 1.18% |
| Varex Imaging Corporation | VREX | Diagnostics & Research | 10.66 | 435.58M | -3.88% | 16.69 | 80.92% |
| Palatin Technologies Inc | PTN | Diagnostics & Research | 21.45 | 419.31M | 4.33% | n/a | -382.57% |
| Myriad Genetics Inc | MYGN | Diagnostics & Research | 4.58 | 415.96M | -3.58% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 37.42 | 1.18B | -2.30% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 33.41 | 967.39M | 0.97% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.25 | 762.94M | -2.23% | 11.62 | 116.21% |
| HUYA Inc | HUYA | Media - Diversified | 3.04 | 688.17M | -7.60% | n/a | 0.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 16.08 | 670.27M | -1.83% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 5.55 | 641.45M | 0.73% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.44 | 531.52M | -0.05% | 13.28 | 2.28% |
| The Marcus Corporation | MCS | Media - Diversified | 15.88 | 510.92M | -0.87% | n/a | 83.32% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 25.21 | 503.97M | -0.79% | n/a | 1.50% |
| AMC Entertainment Holdings Inc | AMC | Media - Diversified | 0.9807 | 354.38M | -4.79% | n/a | -511.14% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.02 | 12.67 | Cheaper |
| Ent. to Revenue | - | 44.00 | - |
| PE Ratio | - | 40.09 | - |
| Price to Book | 7.41 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 51.60 | 59.59 | Par |
| Debt to Equity | 0.00 | -14.36 | Expensive |
| Debt to Assets | 0.00 | 0.34 | Cheaper |
| Market Cap | 1.29B | 13.71B | Emerging |